Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 34Unknown 13Recruiting 12Terminated 9Active not recruiting 6Withdrawn 3Not yet recruiting 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms 1Leukemia, Myeloid, Acute 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × OTHER × Tretinoin × Clear all
NCT01048086 2016-06-21

90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

University of Iowa

Phase 2 Withdrawn
CNSEndocrineNET

Neuroblastoma, Neuroendocrine Tumors

NCT01067274 2015-12-30

ALFA-0703

Acute Leukemia French Association

Phase 3 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01349556 2014-04-23

Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream

Johns Hopkins University

Phase NA Withdrawn

Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡